Cora N. Sternberg, M.D.
Cora N. Sternberg, M.D.

Cora N. Sternberg, M.D.

Medical Oncology
phone icon
phone icon
Specialties
Medical Oncology, Urological Oncology, more

Locations and Appointments


New Patients

Multidisciplinary Prostate Cancer Clinic

525 East 68th Street
Starr 900
New York, NY 10065
US
Call to ScheduleNew and Existing Patients
Existing Patients
Login or sign-up to Connect Patient Portal to make an appointment

Genitourinary (GU) Oncology

520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021
US
Call to ScheduleNew and Existing Patients
Existing Patients
Login or sign-up to Connect Patient Portal to make an appointment
Existing Patients
Login to Connect Patient Portal make an appointment, view documentation or contact your doctor’s office.
NYP Connect App
The NYP Connect App allows you to access convenient services to help manage your health. Access the patient portal, communicate with your doctor, manage appointments, view test results, request prescription refills, pay a bill, and find a doctor.

insurance icon
Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • Aetna - NYP
  • Empire Blue Cross/Blue Shield
  • Empire Blue Cross/Blue Shield Healthplus
  • GHI
  • Health Insurance Plan of NY (HIP)
  • Oxford Health Plans
  • United Healthcare

about icon
About Cora N. Sternberg, M.D.

Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg is known for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.


Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patients with these diseases.


Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.


Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.


At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.


Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.


Dr. Sternberg has published approximately 400 articles in peer-reviewed publications, including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks at prestigious international venues.


Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.


She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.


Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.


This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.


Board Certifications

  • Internal Medicine
  • Medical Oncology
list icon

Expertise

  • Bladder Cancer

  • Genomics

  • Immunotherapy

  • Kidney Cancer

  • Prostate Cancer

  • Testicular Cancer

  • Urologic Cancer

  • Urothelial Cancer

list icon

Education

  • Degrees: University of Pennsylvania

  • Degrees: University of Pennsylvania

  • Degrees: University of Rome Faculty of Medicine and Surgery (Italy)

list icon

Titles & Positions

  • Professor of Medicine

list icon

Hospital Affiliations

  • NewYork-Presbyterian / Weill Cornell Medical Center

Education

  • Degrees: University of Rome Faculty of Medicine and Surgery (Italy)
  • Degrees: University of Pennsylvania
  • Degrees: University of Pennsylvania

Titles & Positions

  • Professor of Medicine

Board Certifications

  • Internal Medicine
  • Medical Oncology

Languages Spoken

  • English
  • Italian